tradingkey.logo

BRIEF-EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

ReutersFeb 5, 2025 12:40 PM

- EyePoint Pharmaceuticals Inc EYPT.O:

  • EYEPOINT ANNOUNCES POSITIVE SIX-MONTH RESULTS FOR THE PHASE 2 VERONA CLINICAL TRIAL OF DURAVYU™ FOR DIABETIC MACULAR EDEMA MEETING PRIMARY AND SECONDARY ENDPOINTS

  • EYEPOINT PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED BY BOTH DURAVYU DOSES

  • EYEPOINT PHARMACEUTICALS INC: PHASE 3 NON-INFERIORITY PIVOTAL PROGRAM INITIATION ANTICIPATED BY END OF 2025 -

  • EYEPOINT PHARMACEUTICALS INC - PHASE 3 NON-INFERIORITY PROGRAM INITIATION EXPECTED BY END OF 2025

  • EYEPOINT PHARMACEUTICALS INC - NO DURAVYU-RELATED OCULAR OR SYSTEMIC SAES REPORTED

Source text: ID:nGNX9wF18z

Further company coverage: EYPT.O

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI